Ciprofloxacin Inhale - A Pharmacokinetic(PK)/pharmacodynamic(PD) Rationale

被引：0
|
作者：
Stass, H. [1 ]
Dalhoff, A. [2 ]
机构：
[1] Bayer Schering Pharma, Wuppertal, Germany
[2] Univ Hosp SH, Kiel, Germany
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2010年 / 181卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1820
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetic/pharmacodynamic (PK/PD) modeling of captopril in healthy volunteers.
    Yi, SY
    Bae, KS
    Lim, HS
    Cho, JY
    Yu, KS
    Jang, IJ
    Shin, SG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P74 - P74
  • [22] Assessment of pharmacokinetic (PK) and pharmacodynamic (PD) interaction between warfarin and repaglinide
    Rosenberg, M
    Strange, P
    Cohen, A
    DIABETES, 1999, 48 : A356 - A356
  • [23] Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMAb
    Bender, B.
    Xiang, H.
    Reyes, A. E., II
    Damico, L. A.
    Merchant, M.
    Peterson, A.
    Forrest, W.
    Jumbe, N. L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 170 - 170
  • [24] Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Once-Daily Treatment Using Ciprofloxacin in an Extended-Release Dosage Form*
    E. L. Schuck
    A. Dalhoff
    H. Stass
    H. Derendorf
    Infection, 2005, 33 : 22 - 28
  • [25] Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form
    Schuck, EL
    Dalhoff, A
    Stass, H
    Derendorf, H
    INFECTION, 2005, 33 (Suppl 2) : 22 - 28
  • [26] DEVELOPMENT OF A PHARMACOKINETIC (PK)/PHARMACODYNAMIC (PD) MODEL TO EVALUATE THE IMPACT OF PK VARIATION ON PD FOR EXTENDED RELEASE METOPROLOL FORMULATIONS
    Sharma, V. D.
    Trame, M. N.
    Schmidt, S.
    Fang, L. L.
    Lesko, L. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S9 - S9
  • [27] In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
    Xiao, Xia
    Lan, Weixuan
    Zhao, Yaqin
    Li, Ruichao
    Liu, Yuan
    Liu, Juan
    Wang, Zhiqiang
    FRONTIERS IN MICROBIOLOGY, 2021, 11
  • [28] Supporting MetMAb entry into the clinic with nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) information
    Xiang, H.
    Reyes, A.
    Merchant, M.
    Bender, B.
    Jumbe, N.
    Young, J.
    Gelzleichter, T.
    Vaidyanathan, A.
    Peterson, A.
    Damico, L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 167 - 167
  • [29] PRACTICAL IMPLICATIONS OF PHARMACOKINETIC AND PHARMACODYNAMIC (PK/PD) MODELING OF DRUG DOSE REGIMENS
    BAGGOT, JD
    EQUINE VETERINARY JOURNAL, 1995, 27 (04) : 245 - 246
  • [30] Population pharmacokinetic (PK)-pharmacodynamic (PD) model for gefitinib in cancer patients.
    Li, J
    Karlsson, MO
    Brahmer, J
    Cusatis, G
    Hidalgo, M
    Baker, SD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 212S - 212S
12345